

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Neurofibromin 1 (D7R7D) Rabbit mAb

RRID:AB_2798543

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 14623, RRID:AB_2798543

Antibody Information

URL: http://antibodyregistry.org/AB_2798543

Proper Citation: Cell Signaling Technology Cat# 14623, RRID:AB_2798543

Target Antigen: NF1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: Neurofibromin 1 (D7R7D) Rabbit mAb

Description: This monoclonal targets NF1

Target Organism: h, m, r, mk

Clone ID: Clone D7R7D

Antibody ID: AB_2798543

Vendor: Cell Signaling Technology

Catalog Number: 14623

Record Creation Time: 20250820T022136+0000

Record Last Update: 20250820T132248+0000

Ratings and Alerts

No rating or validation information has been found for Neurofibromin 1 (D7R7D) Rabbit mAb.

No alerts have been found for Neurofibromin 1 (D7R7D) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. *Cancer research*, 86(15), 3819.

Ni J, et al. (2026) CD70 regulates the NF1/Ras/ERK axis to promote metastatic potential in clear cell renal cell carcinoma. *Cancer cell international*, 26(1).

Williams KB, et al. (2025) Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors. *Molecular cancer therapeutics*.

Ibrahim M, et al. (2025) NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma. *Cancer research*, 85(17), 3348.

Olsen SN, et al. (2025) Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. *Cell reports. Medicine*, 6(7), 102192.

Zhang J, et al. (2025) An integrated proteomic portrait of prostate cancer progression. *Cell reports*, 44(6), 115828.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. *EMBO reports*, 25(9), 3944.

Ramakrishnan G, et al. (2022) NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. *Cell reports*, 41(6), 111623.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. *Cell reports*, 40(4), 111095.

Zheng ZY, et al. (2020) Neurofibromin Is an Estrogen Receptor-?? Transcriptional Co-repressor in Breast Cancer. *Cancer cell*, 37(3), 387.

Carnes RM, et al. (2019) Affinity Purification of NF1 Protein-Protein Interactors Identifies Keratins and Neurofibromin Itself as Binding Partners. *Genes*, 10(9).